



Oxford Nanopore
Technologies

Transforming the future of clinical genetic testing

Dr Ahmad Abou Tayoun is focused on improving diagnosis for patients with rare diseases in the Middle East. Find out how he has uncovered 10% more potential diagnoses¹, changing the face of clinical genetic testing.

'... our results demonstrate the potential of long-read sequencing as a single unified assay for routine clinical genetic testing and the discovery of novel rare disease variations'¹

Dr Ahmad Abou Tayoun
Clinical Molecular Geneticist



Revealing more to transform human health

Ask bolder questions

Identifying pathogenic variants in patients with rare disease is essential for timely treatment. With current methodologies, patients can wait for years to receive a diagnosis, and around half remain undiagnosed^{1,2}. The diverse spectrum of disease-causing variants requires a flexible platform to provide scalable and cost-effective solutions.

Ultra-rich data

10%

more potential diagnoses¹

Novel SMA

methylation profile detected¹

<48 hours

time to answer³

Reveal more biology

Dr Tayoun *et al.* found that variants of any length and methylation patterns could be identified in a single, whole-genome Oxford Nanopore sequencing run, uncovering pathogenic changes in 10% of individuals with rare diseases and prior inconclusive tests¹. He also explored nanopore sequencing for its capacity as a single screening test for spinal muscular atrophy (SMA) using a cost-efficient, targeted approach³.

Importantly, the assay is cost-effective and scalable, showing potential for broad implementation in diagnostic and screening programs^{1,3}



Read more about clinical research with Oxford Nanopore sequencing

References

1. Sinha, S... Tayoun, A.A. *Nat. Comms.* (2025). DOI: <https://doi.org/10.1038/s41467-025-57695-9>
2. Tayoun, A.A. Presentation. Available at: <https://nanoporetech.com/resource-centre/london-calling-2023-nanopore-sequencing-potential-diagnostic-tool-genetic-diseases> [Accessed 26 April 2024]
3. Hall, B... Tayoun, A.A. *medRxiv* (2024). DOI: <https://www.medrxiv.org/content/10.1101/2024.02.22.24303180v1>



Oxford
Nanopore
Technologies

www.nanoporetech.com

phone +44 (0)845 034 7900

email support@nanoporetech.com

 [oxford-nanopore-technologies](https://www.linkedin.com/company/oxford-nanopore-technologies)

 [@nanopore](https://twitter.com/nanopore)

 [@nanoporetech.com](https://www.facebook.com/nanoporetech.com)

Oxford Nanopore Technologies and the Wheel icon are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may be protected by patents or patents pending of Oxford Nanopore Technologies plc. © 2025 Oxford Nanopore Technologies plc. All rights reserved. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition. FL_1251(EN)_V2_18Mar2025